Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population

Rheumatology International

Volumn 32, Issue 10, 2012, Pages 3127-3130

  Chen, Jinwei ^a   Chen, Lixiao ^a   Mao, Ni ^a   Liu, Yiming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Multidrug resistant gene 1; P glycoprotein; Refractory rheumatoid arthritis; SNP

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CHINESE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; DRUG RESISTANCE; EXONS; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ODDS RATIO; P-GLYCOPROTEIN; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE;

EID: 84867843061     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2088-3     Document Type: Article

References (14)

1. Liu F, Wang C, Zhang Q, Li J, Zhang Y (2002) Establishment of multidrug resistance cell line C6/adr and reversal of drug resistance. Clin Med J (Engl) 115(2):238
2. Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62(11):933-937
3. Marchetti S, Mazzanti R, Beijnen JH, Jan Schellensa HM (2007) Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927-941
4. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67(3):380-388
5. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496-503
6. Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herezynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933-937
7. Mc Carthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18(5):505
8. Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics 11(3):217-221
9. Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H et al (2000) Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30-39
10. Rahgu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-Glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258-1264
11. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et al (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2, IL-4, and interferon-gamma in normal human T lymphocytes. Blood (88):1747-1754
12. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
13. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137-1143
14. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704